Advanced Breast CancerPhase 3DB-GuideNCT07683754
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
A Phase 3 study testing Trastuzumab deruxtecan, Trastuzumab and Pertuzumab in people with Advanced Breast Cancer and Metastatic Breast Cancer, run by Daiichi Sankyo at 5 sites in United States.
Trial summary
This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive
- What is being tested?
- Trastuzumab deruxtecan, Trastuzumab and Pertuzumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 5 sitesUnited States
- Study dates
- 18 Sep 2026to 28 Aug 2030
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures.
- Participant must be ≥18 years of age at the time the ICF is signed.
- Have pathologically documented breast cancer that:
- Is locally advanced and unresectable or metastatic (participants who can be treated with curative intent are not eligible).
- Participant must have histologically confirmed HER2+ and HR+ (ER+ and/or PR+), mBC. ER, PR, and HER2 measurements should be locally performed according to institutional guidelines.
- Is documented by local testing as HR-positive (either ER and/or PgR positive [ER or PgR ≥1%]) per ASCO/CAP guidelines in the metastatic setting or from the primary tumor with the latest sample available.
Show all 20Show fewer
- Has not received prior chemotherapy or HER2-targeted therapy for mBC. Participant who has received chemotherapy or HER2-targeted therapy or radiotherapy or surgery in the neoadjuvant or adjuvant setting are eligible, with a DFI of >6 months (>183 days) from completion of systemic chemotherapy or any HER2-targeted therapy (antibody, TKI or T-DM1) to diagnosis of advanced or metastatic disease.
- ECOG PS of 0 or 1 assessed no more than 3 days prior to initiation of trial intervention.
- Has at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI, which is suitable for accurate repeated measurements, or nonmeasurable, bone-only disease that can be assessed by CT, MRI, or X-ray.
- Participant with brain metastases are allowed if participant is asymptomatic and does not require immediate local intervention.
- Additional Key Criteria to Transition into the Maintenance Treatment Phase
- 1. Participant transitioning into the Maintenance Treatment Phase must meet the following inclusion criteria for Maintenance Treatment:
- Participant is without evidence of disease progression under T-DXd + pertuzumab treatment by local assessment according to RECIST v1.1 (ie, CR, PR, or SD), and
- Participant is willing to switch therapy, and
- Participant completed at least 8 cycles of T-DXd + pertuzumab and achieved cCR (confirmation of CR should be obtained during the next protocol defined scheduled tumor assessment.), or
- Participant completed 18 cycles (in total) of T-DXd and achieved a SD or PR, and the last 2 scans showed no further tumor shrinkage (defined as 2 subsequent scans at least 6 weeks apart) or has an unconfirmed CR.
- Additional Key Criteria for T-DXd Retreatment Phase
- Has received at least 1 dose of Maintenance Treatment.
- Has documented disease progression per RECIST v1.1 per investigator assessment during Maintenance Treatment.
- Participant who experienced ILD Grade 1 during the Maintenance Treatment Phase, must have fully resolved before starting T-DXd during the Retreatment Phase.
Who cannot join
- Has prior therapy with any CDK inhibitor.
- Previous T-DXd therapy for early BC with an EFS or disease-free interval of < 12 months from completion of T-DXd therapy in the neoadjuvant or post-neoadjuvant setting.
- Is receiving concurrent therapy with other trial interventions (except pertuzumab which is part of Upfront Treatment and Maintenance Treatment).
- Has prior therapy with any CDK inhibitor.
- Has any unresolved SAE related to prior T-DXd + pertuzumab treatment from the Upfront Treatment Phase, defined as an event that has not resolved to baseline by the time of the eligibility assessment for the Maintenance Treatment Phase.
- Has experienced Grade 3 or 4 ILD/pneumonitis during the Upfront Treatment Phase.
Show all 10Show fewer
- Has spinal cord compression or clinically active CNS metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- Participant who developed ILD/pneumonitis Grade ≥2 during the Upfront Treatment Phase or Maintenance Treatment Phase.
- Participant has any unresolved SAE related to prior Maintenance Treatment Phase therapies defined as an event that has not resolved to baseline by the time of the eligibility assessment for the T-DXd Retreatment Phase.
- Participant who developed non-ILD toxicities related to T-DXd in the Upfront Treatment Phase that required T-DXd discontinuation.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
Maryland Oncology Hematology, P.A.
Columbia, Maryland, 21044
Principal Investigator
- Recruiting
Texas Oncology - West Texas
El Paso, Texas, 79902
Principal Investigator
- Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89144
Principal Investigator
- Recruiting
SCRI Oncology Partners
Nashville, Tennessee, 37203
Principal Investigator
- Recruiting
Texas Oncology - San Antonio
New Braunfels, Texas, 78130
Principal Investigator
About this study
Official title: A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)
This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.
Read the detailed description
This global, interventional, open-label, phase 3b trial will evaluate the efficacy and safety of a sequential treatment approach for first-line HER2+/HR+ advanced/metastatic breast cancer, initiating with upfront T-DXd + pertuzumab administered for 18 to 24 cycles, followed by a transition to trastuzumab + pertuzumab + ET + palbociclib. Participants who experience disease progression while receiving trastuzumab + pertuzumab + ET + palbociclib will receive T-DXd as 2L therapy.
The study objectives will assess efficacy, safety, and quality-of-life in patients with advanced/metastatic breast cancer.
- Being tested
- Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib
- Keywords
- Advanced Breast Cancer, Metastatic Breast Cancer, T-DXd, HER2 positive, HR positive
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Trastuzumab deruxtecanDrug
Also called T-DXd, ENHERTU®
Upfront treatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle
T-DXd Retreatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle
*Dose reductions implemented during Upfront treatment phase will be maintained.
TrastuzumabDrug
Also called Herceptin®
Maintenance treatment: One IV infusion Q3W 6 mg/kg on Day 1 of each 21-day cycle
PertuzumabDrug
Also called Perjeta®
Upfront treatment: One IV infusion Q3W loading dose of 840 mg, then 420 mg Q3W thereafter on Day 1 of each 21-day cycle
Maintenance treatment:
One IV infusion Q3W 420 mg on Day 1 of each 21-day cycle
Endocrine TherapyDrug
Aromatase inhibitors or fulvestrant administered as approved product label
PalbociclibDrug
Also called Ibrance®
Maintenance treatment:
Daily (3 out of 4 weeks, Q4W) oral 125 mg
| Study group | Role | What they receive |
|---|---|---|
| T-DXd | Experimental | Adult participants with previously untreated advanced or metastatic HER2+/HR+ breast cancer who will receive T-DXd intravenously every 3 weeks (IV Q3W) in 3 treatment phases:
Upfront treatment phase:
T-DXd + pertuzumab IV Q3W
Maintenance treatment phase:
Trastuzumab + palbociclib + endocrine therapy + pertuzumab IV Q3W
T-DXD retreatment phase:
T-DXd monotherapy IV Q3W Receives: Drug: Trastuzumab deruxtecan; Drug: Trastuzumab; Drug: Pertuzumab; Drug: Endocrine Therapy; Drug: Palbociclib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free Survival (PFS) Rate at 24 Months
PFS is defined as the time from initiation of T-DXd + pertuzumab until PD or death, whichever occurs first.
Measured: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Secondary outcomes (18)
Progression-free Survival (PFS) Rate at 12 Months
PFS is defined as the time from initiation of T-DXd + pertuzumab until PD or death, whichever occurs first.
Measured: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 12 months
Objective Response Rate
ORR is defined as the proportion of participants with measurable disease at baseline who have a CR or PR during the Upfront Treatment Phase.
Measured: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Progression-free Survival (PFS) Rate From Start of Maintenance Treatment at 12 Months
PFS from start of Maintenance Treatment is defined as the time from initiation of Maintenance Treatment until PD or death, whichever occurs first.
Measured: From start of Maintenance Treatment until disease progression (PD) or death, whichever occurs first, up to approximately 12 months
Overall Survival at 24 Months
OS is defined as the time from initiation of T-DXd + pertuzumab until the date of death due to any cause.
Measured: From start of Upfront Treatment phase until the date of death, up to approximately 24 months
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death
Measured: From start of T-DXd Retreatment phase up to approximately 24 months
Time to First AESI and TEAE
Measured: From start of T-DXd Retreatment phase up to approximately 24 months
Objective Response Rate
Measured: From start of T-DXd Retreatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Change From Maintenance Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, and Symptom Scales.
The EORTC-QLQ-C30 includes both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high-level of symptomatology/problems.
Measured: From start of Maintenance Treatment phase until approximately 24 months
Change From Maintenance Treatment Baseline in EQ-5D-5L Overall Score
The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity. A unique health state (EQ-5D-5L profile) is defined by the combination of responses across the 5 dimensions and is represented as a five-digit code. The EQ-5D-5L profile will be converted into a health state utility index value reported here.
Measured: From start of Maintenance Treatment phase until approximately 24 months
Change From Maintenance Treatment Baseline in EQ-5D-5L Dimension-specific Scores
The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity.
Measured: From start of Maintenance Treatment phase until approximately 24 months
Change From Maintenance Treatment Baseline in EQ-VAS
The EQ-VAS records the participant's self-rated health on a vertical visual analogue scale ranging from 0 to 100, where: 0 represents "the worst imaginable health", and 100 represents "the best imaginable health". Higher scores indicate worse clinical outcome.
Measured: From start of Maintenance Treatment phase until approximately 24 months
Time to Deterioration/Improvement After the Transition to Maintenance Treatment Phase
Measured: From start of Maintenance Treatment phase until approximately 24 months
Change From Upfront Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, Symptom Scales.
The EORTC-QLQ-C30 includes both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high-level of symptomatology/problems.
Measured: From start of Upfront Treatment phase to end of Maintenance Treatment phase, up to approximately 24 months
Change From Upfront Treatment Baseline in EQ-5D-5L Overall Score
The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity. A unique health state (EQ-5D-5L profile) is defined by the combination of responses across the 5 dimensions and is represented as a five-digit code. The EQ-5D-5L profile will be converted into a health state utility index value reported here.
Measured: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months
Change From Upfront Treatment Baseline in EQ-5D-5L Dimension-specific Scores
The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity.
Measured: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months
Change From Upfront Treatment Baseline in EQ-VAS
The EQ-VAS records the participant's self-rated health on a vertical visual analogue scale ranging from 0 to 100, where: 0 represents "the worst imaginable health", and 100 represents "the best imaginable health". Higher scores indicate worse clinical outcome.
Measured: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death
Measured: From start of Upfront Treatment phase up to approximately 24 months
Time to First AESI and TEAE
Measured: From start of Upfront Treatment phase up to approximately 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start18 Sep 2026
- Primary completion4 Jul 2030 (estimated)
- Study completion28 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Breast CancerStudies of the same condition, open and under way.
- More trials run by Daiichi SankyoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Daiichi Sankyo
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- AstraZeneca
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07683754
- Sponsor's protocol ID
- DS8201-0004-CIS-MA
- Acronym
- DB-Guide
- Status last verified
- Oct 2026
- First submitted
- 25 Jun 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)
- ClinicalTrials.gov ID
- NCT07683754
- Acronym / sponsor ID
- DB-Guide / DS8201-0004-CIS-MA
- Keywords
- Advanced Breast Cancer, Metastatic Breast Cancer, T-DXd, HER2 positive, HR positive
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Daiichi SankyoIndustry (pharma, biotech, devices)
- Collaborators
- AstraZeneca
- Study start
- 18 Sep 2026 (actual)
- Primary completion
- 4 Jul 2030 (estimated)
- Study completion
- 28 Aug 2030 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.
Detailed description
This global, interventional, open-label, phase 3b trial will evaluate the efficacy and safety of a sequential treatment approach for first-line HER2+/HR+ advanced/metastatic breast cancer, initiating with upfront T-DXd + pertuzumab administered for 18 to 24 cycles, followed by a transition to trastuzumab + pertuzumab + ET + palbociclib. Participants who experience disease progression while receiving trastuzumab + pertuzumab + ET + palbociclib will receive T-DXd as 2L therapy.
The study objectives will assess efficacy, safety, and quality-of-life in patients with advanced/metastatic breast cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| T-DXd | Experimental | Drug: Trastuzumab deruxtecan, Drug: Trastuzumab, Drug: Pertuzumab, Drug: Endocrine Therapy, Drug: PalbociclibAdult participants with previously untreated advanced or metastatic HER2+/HR+ breast cancer who will receive T-DXd intravenously every 3 weeks (IV Q3W) in 3 treatment phases: Upfront treatment phase: T-DXd + pertuzumab IV Q3W Maintenance treatment phase: Trastuzumab + palbociclib + endocrine therapy + pertuzumab IV Q3W T-DXD retreatment phase: T-DXd monotherapy IV Q3W |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures.
- Participant must be ≥18 years of age at the time the ICF is signed.
- Have pathologically documented breast cancer that:
- Has not received prior chemotherapy or HER2-targeted therapy for mBC. Participant who has received chemotherapy or HER2-targeted therapy or radiotherapy or surgery in the neoadjuvant or adjuvant setting are eligible, with a DFI of >6 months (>183 days) from completion of systemic chemotherapy or any HER2-targeted therapy (antibody, TKI or T-DM1) to diagnosis of advanced or metastatic disease.
- ECOG PS of 0 or 1 assessed no more than 3 days prior to initiation of trial intervention.
Key exclusion criteria (10 listed)
- Has prior therapy with any CDK inhibitor.
- Previous T-DXd therapy for early BC with an EFS or disease-free interval of < 12 months from completion of T-DXd therapy in the neoadjuvant or post-neoadjuvant setting.
- Is receiving concurrent therapy with other trial interventions (except pertuzumab which is part of Upfront Treatment and Maintenance Treatment).
- Has prior therapy with any CDK inhibitor.
- Has any unresolved SAE related to prior T-DXd + pertuzumab treatment from the Upfront Treatment Phase, defined as an event that has not resolved to baseline by the time of the eligibility assessment for the Maintenance Treatment Phase.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Trastuzumab deruxtecanAlso: T-DXd, ENHERTU®Upfront treatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle T-DXd Retreatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle *Dose reductions implemented during Upfront treatment phase will be maintained. | Drug | T-DXd |
| TrastuzumabAlso: Herceptin®Maintenance treatment: One IV infusion Q3W 6 mg/kg on Day 1 of each 21-day cycle | Drug | T-DXd |
| PertuzumabAlso: Perjeta®Upfront treatment: One IV infusion Q3W loading dose of 840 mg, then 420 mg Q3W thereafter on Day 1 of each 21-day cycle Maintenance treatment: One IV infusion Q3W 420 mg on Day 1 of each 21-day cycle | Drug | T-DXd |
| Endocrine TherapyAromatase inhibitors or fulvestrant administered as approved product label | Drug | T-DXd |
| PalbociclibAlso: Ibrance®Maintenance treatment: Daily (3 out of 4 weeks, Q4W) oral 125 mg | Drug | T-DXd |
Primary outcome
Progression-free Survival (PFS) Rate at 24 Months
Time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
PFS is defined as the time from initiation of T-DXd + pertuzumab until PD or death, whichever occurs first.
18 secondary outcomes
Progression-free Survival (PFS) Rate at 12 Months
Time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 12 months
Objective Response Rate
Time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Progression-free Survival (PFS) Rate From Start of Maintenance Treatment at 12 Months
Time frame: From start of Maintenance Treatment until disease progression (PD) or death, whichever occurs first, up to approximately 12 months
Overall Survival at 24 Months
Time frame: From start of Upfront Treatment phase until the date of death, up to approximately 24 months
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death
Time frame: From start of T-DXd Retreatment phase up to approximately 24 months
Time to First AESI and TEAE
Time frame: From start of T-DXd Retreatment phase up to approximately 24 months
Objective Response Rate
Time frame: From start of T-DXd Retreatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Change From Maintenance Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, and Symptom Scales.
Time frame: From start of Maintenance Treatment phase until approximately 24 months
Change From Maintenance Treatment Baseline in EQ-5D-5L Overall Score
Time frame: From start of Maintenance Treatment phase until approximately 24 months
Change From Maintenance Treatment Baseline in EQ-5D-5L Dimension-specific Scores
Time frame: From start of Maintenance Treatment phase until approximately 24 months
Change From Maintenance Treatment Baseline in EQ-VAS
Time frame: From start of Maintenance Treatment phase until approximately 24 months
Time to Deterioration/Improvement After the Transition to Maintenance Treatment Phase
Time frame: From start of Maintenance Treatment phase until approximately 24 months
Change From Upfront Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, Symptom Scales.
Time frame: From start of Upfront Treatment phase to end of Maintenance Treatment phase, up to approximately 24 months
Change From Upfront Treatment Baseline in EQ-5D-5L Overall Score
Time frame: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months
Change From Upfront Treatment Baseline in EQ-5D-5L Dimension-specific Scores
Time frame: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months
Change From Upfront Treatment Baseline in EQ-VAS
Time frame: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death
Time frame: From start of Upfront Treatment phase up to approximately 24 months
Time to First AESI and TEAE
Time frame: From start of Upfront Treatment phase up to approximately 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Related trials for Advanced Breast Cancer
Not yet recruitingPhase 2
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
Breast Cancer, Advanced Breast Cancer
RecruitingPhase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Advanced Solid Tumors, Metastatic Pancreatic Cancer
RecruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
RecruitingPhase 1/2
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Metastatic Triple-Negative Breast Carcinoma
Active, not recruitingPhase 1
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Advanced Cancer, Advanced Malignancies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Trastuzumab deruxtecan, Trastuzumab and Pertuzumab in people with Advanced Breast Cancer and Metastatic Breast Cancer, run by Daiichi Sankyo at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Contact for Clinical Trial Information (908-992-6400, CTRinfo_us@daiichisankyo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free Survival (PFS) Rate at 24 Months (time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.